---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-031141"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T21:29:08.355253+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# KidneyIntelX included in final KDIGO 2024 guideline for CKD risk prediction

## Summary
- KidneyIntelX recommended for predicting CKD progression in stages G1-G3 per KDIGO 2024 guideline released March 13.
- FDA de-novo marketing authorization for kidneyintelX.dkd received June 2023 for use in type 2 diabetes patients.
- Outcomes data from >2,500 patients showed sustained reduction in eGFR decline and improved diabetes/cardiovascular management.
- Current enrollment >9,000 patients with type 2 diabetes and CKD for ongoing clinical utility and outcomes studies.
- Guideline emphasizes risk prediction and personalized treatment; Renalytix aims to expand evidence base.

## SEC filing metadata
- accession: 0000950170-24-031141
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017024031141/0000950170-24-031141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017024031141/rnlx-20240314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-031141
- JSON: https://secwatch.observer/filing/0000950170-24-031141.json
- Plain text: https://secwatch.observer/filing/0000950170-24-031141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.